Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors

ChangHong; Han-ZhiDong; Rui-NingLiHong-BoZhuQi-MeiLiHaoCuiCheng-YiHuChao-YiHuangJiePengLiLiuXue-JingZouLu-ShanXiao

首页> 外文期刊>Digestive diseases >Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors

【24h】

Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors

机译：Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Background: Immune checkpoint inhibitors (ICIs) have improved survival outcomes and resulted in long-term responses in primary liver cancer in some patients. Nevertheless, not all patients with PLC could benefit from immunotherapy. Therefore, it is necessary to identify patients suitable for such therapy. Methods: 215 patients with primary liver cancer with immunotherapy from Nanfang Hospital were screened between August 2018 and October 2020 as a training set and our validation set included 71 patients of hepatocellular carcinoma from Jiangxi Cancer Hospital from May 2019 to July 2021. The primary endpoint was the disease control rate (DCR), and the secondary endpoints were overall survival (OS) and progression-free survival. Results: In the training set, neutrophil-lymphocyte ratio (NLR) ≥3 and alpha-fetoprotein (AFP) level ≥20 ng/mL were independently associated with non-DCR in the training set after adjusting for distant metastasis at baseline and targeted therapy combination. Furthermore, a hepatic immune predictive index (HIPI) based on NLR and AFP level was developed and patients with poor HIPI associated with worse clinical outcomes. In validation set, high HIPI was associated with poor OS. Conclusion: HIPI, based on NLR and AFP level, is an effective indicator in ICI-treated patients with primary liver cancer. Our findings may help guide the selection and on-treatment strategies for immunotherapies for primary liver cancer patients.

著录项

来源
《Digestive diseases》 |2023年第3期|422-430|共9页
作者
ChangHong; Han-ZhiDong; Rui-NingLiHong-BoZhuQi-MeiLiHaoCuiCheng-YiHuChao-YiHuangJiePengLiLiuXue-JingZouLu-ShanXiao;
展开▼
作者单位

Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China;

Department of Medical Oncology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang;

Department of Medical Oncology, The First Affiliated Hospital, Hengyang Medical School, UniversityDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Infectious Diseases, Guangzhou First People’s Hospital, Guangzhou, China;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类消化系及腹部疾病;
关键词
Alpha-fetoprotein; Hepatic immune predictive index; Immune checkpoint inhibitors; Neutrophil-lymphocyte ratio; Primary liver cancer;

Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors

摘要

著录项

相关主题

期刊订阅